Omeros Corporation (NASDAQ:OMER) Receives Average Rating of “Moderate Buy” from Analysts

Omeros Corporation (NASDAQ:OMER) has earned an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, three have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $27.50.

OMER has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Omeros from a “sell” rating to a “hold” rating in a research note on Saturday, September 20th. HC Wainwright upped their target price on shares of Omeros from $9.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, October 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Wednesday, October 15th. WBB Securities reissued a “strong-buy” rating and set a $45.00 price target on shares of Omeros in a research report on Wednesday, October 15th. Finally, D. Boral Capital reissued a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Wednesday, October 15th.

Omeros Trading Down 1.2%

Shares of NASDAQ OMER opened at $7.65 on Friday. The firm has a market cap of $520.66 million, a PE ratio of -3.63 and a beta of 2.32. Omeros has a 1-year low of $2.95 and a 1-year high of $13.60. The company has a fifty day moving average price of $4.87 and a 200 day moving average price of $4.56.

Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.02. The company had revenue of $28.60 million during the quarter, compared to analyst estimates of $0.31 million. Equities research analysts forecast that Omeros will post -3.09 EPS for the current year.

Institutional Investors Weigh In On Omeros

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC lifted its position in Omeros by 99.7% during the 3rd quarter. SG Americas Securities LLC now owns 45,324 shares of the biopharmaceutical company’s stock worth $186,000 after buying an additional 22,623 shares in the last quarter. B. Riley Wealth Advisors Inc. bought a new stake in Omeros during the 2nd quarter worth about $32,000. Newbridge Financial Services Group Inc. bought a new stake in Omeros during the 2nd quarter worth about $280,000. Tower Research Capital LLC TRC lifted its position in Omeros by 829.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 11,971 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in Omeros by 548.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 25,272 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 21,376 shares in the last quarter. 48.79% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.